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Interleukin-1b (IL-1b) secretion downstream of Toll-like receptor (TLR) activation is tightly con-
trolled at the transcriptional and post-translational levels. NLRP3 inﬂammasome is involved in
the maturation of pro-IL-1b, with NLRP3 expression identiﬁed as the limiting factor for inﬂamma-
some activation. Previously, we had demonstrated that the zinc-ﬁnger protein GFI1 inhibits
pro-IL-1b transcription. Here, we show that GFI1 inhibits NLRP3 inﬂammasome activation and
IL-1b secretion in macrophages. GFI1 suppressed Nlrp3 transcription via two mechanisms: (1) by
binding to the Gli-responsive element 1 (GRE1) in the Nlrp3 promoter; and (2) by antagonizing
the nuclear factor-jB (NF-jB) transcriptional activity. Thus, GFI1 negatively regulates TLR-mediated
IL-1b production at both transcriptional and post-translational levels.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction which, in turn, proteolytically cleaves pro-IL-1b to release matureInnate immune cells initiate an immediate response to
pathogens by generating abundant pro-inﬂammatory cytokines,
including interleukin-1b (IL-1b), which exerts a wide range of
inﬂammatory and antimicrobial activities [1–3]. Production of
IL-1b is under tight regulation and requires a two-step process:
(1) Toll-like receptor (TLR) and NF-jB signaling-dependent
transcription and translation resulting in an inactive precursor,
pro-IL-1b, and (2) inﬂammasome-mediated cleavage of pro-IL-1b
into mature biologically active IL-1b [4,5].
Inﬂammasome is a multiprotein complex critical for IL-1b mat-
uration and release [6,7]. The complex is generally composed of
pro-caspase-1, adaptor protein apoptosis-associated speck-like
protein (ASC) and one of the NOD-like receptor (NLR) family mem-
bers, such as NLRP1 (NOD-like receptor containing pyrin 1), NLRP3
and NLRC4 (NOD-like receptor containing CARD) [8–10]. Upon
stimulation with a myriad of microbial and endogenous signals,
NLR is activated to assemble the inﬂammasome and sequentially
primes auto-catalysis of pro-caspase-1 into active caspase-1,IL-1b [11–14].
Among the NLR family members, NLRP3 is the most sensitive
receptor that can be activated by a broad range of pathogen-
associated molecular patterns [13,15,16]. The NLRP3 inﬂamma-
some is particularly important for IL-1b production. Although
several stimuli effectively trigger NLRP3 [17,18], one established
mechanism for regulating its expression involves the TLR/MyD88
pathway, which is tightly controlled by signals culminating into
activation of NF-jB [19,20].
Since NLRP3 expression is a critical checkpoint for inﬂamma-
some activation [19,21], negative regulatory mechanisms that sup-
press NLRP3 are necessary to control excessive IL-1b production
during sepsis [22,23]. Recently, miR-223 was shown to suppress
NLRP3 expression. However, since miR-223 itself is not regulated
by pro-inﬂammatory signals, it may act like a rheostat to tightly
control the NLRP3 message for basal protection [24].
Growth factor independence 1 (Gﬁ1) encodes a 55 kDa nuclear
zinc ﬁnger transcription factor with an N-terminal SNAG domain
and a six C-terminal zinc ﬁnger motifs linked by an intermediary
region [25,26]. Gﬁ1 acts as a transcriptional repressor by binding
to a DNA recognition sequence in target gene promoters [26–28].
Transcriptional repression activity of Gﬁ1 is dependent on the zinc
ﬁnger motifs required for DNA binding as well as the intact
N-terminal SNAG domain responsible for nuclear localization
[26,28]. In addition, Gﬁ1 harbors functions independent of its
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with the STAT3 (signal transducer and activator of transcription
3) inhibitor PIAS3 (protein inhibitor of activated STAT 3) and the
p65 subunit of NF-jB via its intermediary region [29,30].
Earlier studies revealed that Gﬁ1-deﬁcient mice exhibit defects
in development of hematopoietic and immune systems as well as
excessive endotoxin-initiated innate immune responses [31–35].
Gﬁ1-deﬁcient mice are highly susceptible to lipopolysaccharide
(LPS)-induced septic shock due to overproduction of pro-
inﬂammatory cytokines [31]. Recently, Gﬁ1 was shown to inhibit
TLR-mediated production of TNF-a through binding p65 of NF-jB
and consequently interfering with p65 binding to target gene pro-
moter DNA [30]. In addition, the ﬁnding that Gﬁ1-deﬁcient macro-
phages display higher levels of IL-1b mRNA than their wild-type
counterparts after LPS stimulation suggests that Gﬁ1 negatively
regulates IL-1b production at the transcriptional level [30].
In the present study, we investigated whether Gﬁ1 regulates
TLR-mediated production of IL-1b at the post-transcriptional
stages. The promoter sequence of Nlrp3 contains two NF-jB bind-
ing elements [20]. Screening of the promoter sequence revealed
two putative Gﬁ1 binding sites containing the consensus motif
AATC. Our data suggest that Gﬁ1 inhibits NLRP3 expression via
two different pathways, either by binding directly to the promoter
cis-element or antagonizing NF-jB p65 transcriptional activity,
leading to subsequent effects on IL-1b maturation.
2. Materials and methods
2.1. Mice
Gﬁ1/ mice were kindly provided by Professor Tarik Möröy
(Institut de recherches cliniques de Montréal, Canada). Mice were
housed under speciﬁc pathogen-free conditions at the Institute of
Laboratory Animal Science, Chinese Academy of Medical Sciences,
and Peking Union Medical College. Mouse treatments were
approved by the local animal research committee at the Institute
of Laboratory Animal Sciences.
2.2. Plasmids
WT and NRE mutant Nlrp3 promoters were a kind gift from
Professor Chengjiang Gao, including the full-length Nlrp3 promoter
(nt 3033/+116), functional promoter (nt 1434/1113), mut-
NRE1 (nt 1434/1113, referred to as mutA in their report), mut-
NRE2 (nt 1434/1113, referred to as mutB) and mutNRE1/2 (nt
1434/1113, referred to as mutAB) [20]. The mutGRE1, mutGRE2
and mutGRE1/2 promoters were constructed by mutation of GRE1
and/or GRE2 sequence based on the full-length Nlrp3 promoter (nt
3033/+116). The mutNRE1/GRE1 promoter (nt 1434/1113)
was generated by mutation of GRE1 (AATC to GGAG) based on
the mutNRE1 promoter using the GBclonart Seamless Cloning
and Assembly Kit (Genebank Biosciences Inc). All promoters were
cloned into the pGL3-basic reporter vector. NF-jB p65 and various
Gﬁ1 expression plasmids were kindly provided by Professor Tarik
Möröy, including Gﬁ1-FL (full-length),DSNAG (SNAG domain dele-
tion), DIM (intermediate region deletion) and DZF (zinc ﬁnger
motif deletion). All plasmids were conﬁrmed by DNA sequencing.
2.3. Stimulation of bone marrow-derived macrophages
Bone marrow-derived macrophages (BMDM) were differenti-
ated from bone marrow cells of 6- to 8-week-old C57BL/6
Gﬁ1-deﬁcient mice and their wild-type (WT) littermates, as
described previously [30]. Unless otherwise indicated, cells were
primed for 4 h with 100 ng/ml LPS (Sigma–Aldrich) beforetreatment with 5 mM ATP (Sigma–Aldrich) for a further 45 min.
Supernatant fractions were collected for ELISA, and the cells lysed
for RNA and protein isolation.
2.4. Cell culture, transfection and dual-luciferase reporter assay
293ET cells were cultured in DMEM with 10% FBS and 1% pen-
icillin–streptomycin. For the luciferase reporter assay, 5  104 cells
were cultured on a 24-well plate and subsequently transfected
with a mixture of the indicated expression plasmids, promoter ﬁre-
ﬂy luciferase reporters and Renilla luciferase plasmid (pRL-TK)
using VigoFect reagent (Vigorous Biotechnology). After 24 h, lucif-
erase assays were performed using a dual-Luciferase Reporter
Assay System (Promega), according to the manufacturer’s instruc-
tions. Relative luciferase activity was calculated by normalizing the
ratio of ﬁreﬂy/Renilla luciferase.
2.5. Electrophoretic mobility shift assay (EMSA)
In total, 2  106 293ET cells were cultured in a 60 mm dish and
transfected with 5 lg Gﬁ1 expression plasmids or the vehicle con-
trol for 48 h. WT and Gﬁ1-deﬁcient BMDMs were stimulated with
100 ng/ml LPS for 4 h before nuclear protein extraction. Nuclear
extracts were prepared from 293ET cells or BMDMs using the
NE-PER Nuclear and Cytoplasmic Extraction Kit (Pierce). EMSA
was conducted with Light Shift Chemiluminescent EMSA Kit
(Pierce) using the manufacturer’s protocol. Oligonucleotide probes
were labeled with biotin. The sequences of the GRE1 and NRE1
probes were 50-CAGATGAGTAACTGCCAATCCGTCTTTGACAGTG-30
and 50-AGGCTTCTGCAGGGAACCCCCGGGAATTCT-30, respectively.
In competitive binding assays, unlabeled oligonucleotides were
added at 200-fold molar excess. For supershift assay, 3 lg
anti-Gﬁ1 antibody (Santa Cruz) was added.
2.6. Chromatin immunoprecipitation assay and PCR (ChIP–PCR)
BMDMs were stimulated with 100 ng/ml LPS for 1 h and ChIP–
PCR assay performed as described previously [36]. Input samples
corresponded to 0.5% (v/v) of the total solution before immunopre-
cipitation. Puriﬁed chromatin was immunoprecipitated with 4 lg
anti-Gﬁ1 antibody (Santa Cruz) or IgG. After DNA puriﬁcation,
the presence of speciﬁc DNA sequences was assessed using PCR.
The primers used were 50-CTCCACACACTGGTTCTGCTTG-30 (for-
ward) and 50-AGCAGCCTTGGGTACAAATAAAG-30 (reverse) for the
GRE1 element (proximal region), and 50-TTCTTCAAGGTCATTA
GTGGCTTC-30 (forward) and 50-AGTGCTAAAGGCCTAAGCAGATC-30
(reverse) for the negative control (distal region). The intensities
of bands were quantiﬁed with Image J software (National Institutes
of Health, Maryland, USA).
2.7. Real-time PCR
Total RNA was isolated with TRIzol reagent (Life Technology)
according to the manufacturer’s instructions. RNA (2 lg) was
reverse-transcribed to cDNA using the High Capacity cDNA Reverse
Transcription kit (Life Technology), and speciﬁc transcripts quanti-
ﬁed using the Applied Biosystems 7500 Real-Time PCR System
(Life Technology). Quantitative real-time PCR was performed using
TaqMan Gene Expression Master Mix and TaqMan probes
according to the manufacturer’s instructions (Life Technology).
2.8. Western blot
Whole cell extracts (20 lg) were used for Western blot analysis
with primary antibodies against IL-1b (Abcam), NLRP3 (AdipoGen),
Fig. 1. Gﬁ1 inhibits NLRP3 inﬂammasome activity and NLRP3 expression in macrophages. WT and Gﬁ1/ macrophages were primed with 100 ng/ml LPS for 4 h and
stimulated with or without 5 mM ATP for 45 min. (A) IL-1b secretion in supernatants was measured using ELISA. (B) Whole-cell proteins were subjected to Western blot for
pro-IL-1b, mature IL-1b, pro-caspase-1, cleaved caspase-1 (p10), ASC and NLRP3. b-Actin was detected as the loading control. (C) The mRNA levels of Nlrp3, Nlrp1a and Asc
were quantiﬁed with real-time PCR. Values were normalized to those of Gadph and expressed relative to WT control cells (Ctrl). Representative results from three
independent experiments are shown. ⁄P < 0.05; ⁄⁄⁄P < 0.001.
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(Santa Cruz).
2.9. Measurement of cytokine production
BMDMs were seeded in 96-well plates and cultured overnight.
After priming with 100 ng/ml LPS for 4 h and stimulating with
5 mM ATP for another 45 min, supernatant fractions were collected
and IL-1b concentrations measured using the mouse IL-1b ELISA
set (BD Biosciences Pharmingen), according to the manufacturer’s
instructions.
2.10. Statistical analysis
Data are presented as means ± S.D. of three independent exper-
iments. Statistical differences were determined with the Student’s
t-test, and P values < 0.05 considered statistically signiﬁcant.
3. Results and discussion
3.1. Secretion of IL-1b is increased in Gﬁ1-deﬁcient macrophages
Our previous experiments disclosed signiﬁcantly higher levels
of IL-1b in sera of Gﬁ1-deﬁcient mice treated with LPS [31], indi-
cating that Gﬁ1 inhibits cytokine production upon endotoxin chal-
lenge. To conﬁrm the potential regulatory activity of Gﬁ1 on IL-1b
production, WT and Gﬁ1/ BMDMs were primed with LPS and
subsequently stimulated with ATP. Consistent with previous
in vivo ﬁndings [31], Gﬁ1-deﬁcient BMDMs exhibited a slightincrease in IL-1b production in culture medium than WT BMDMs
in response to LPS stimulation alone, and a more dramatic release
of IL-1b when stimulated with LPS and ATP (Fig. 1A). Moreover,
Western blot analysis revealed a signiﬁcant increase in mature
IL-1b in Gﬁ1-deﬁcient BMDMs (Fig. 1B and Suppl. 1). The data col-
lectively suggest that Gﬁ1 inhibits maturation of IL-1b.
3.2. Gﬁ1 inhibits inﬂammasome activation and NLRP3 expression
Since caspase-1 activity is essential for cleavage of pro-IL-1b
into the mature form, we assessed cleavage of caspase-1 upon
LPS/ATP stimulation in WT and Gﬁ1-deﬁcient macrophages.
Compared with WT, Gﬁ1/ BMDMs exhibited increased levels of
caspase-1 after LPS/ATP stimulation, indicating elevated auto-
catalysis of pro-caspase-1. Consistent with enhanced caspase-1
cleavage, we detected higher levels of NLRP3, but unaltered ASC
expression in Gﬁ1/ BMDMs (Fig. 1B). Real-time PCR revealed
increased Nlrp3 mRNA levels in Gﬁ1-deﬁcient macrophages
(Fig. 1C), implying that Gﬁ1 affects expression of Nlrp3 at the tran-
scriptional level.
3.3. Gﬁ1 inhibits Nlrp3 transcription through direct binding to
promoter DNA
In view of the ﬁnding that Gﬁ1 represses target genes by bind-
ing the response element in the promoter region, we further exam-
ined whether Gﬁ1 acts as a transcriptional regulator of Nlrp3
through binding to its promoter DNA. 293ET cells were transfected
with the mouse Nlrp3 promoter reporter, Gﬁ1 and activator NF-jB
Fig. 2. Gﬁ1 inhibits Nlrp3 transcription by binding the GRE1 element in the promoter. (A) 293ET cells were transfected with 3 ng pRL-TK, 150 ng full-length Nlrp3 promoter
reporter (nt 3033/+116) or pGL3-basic vehicle vector, 300 ng Gﬁ1 expression plasmid or pcDNA3.1 and 150 ng p65 expression plasmid for 24 h. Luciferase activities were
measured and normalized to that of Renilla luciferase. (B) Alignment of the Gﬁ1 binding site consensus with the two potential GRE sites. The core sequence is in uppercase.
Schematic of GRE1 and GRE2 location within the Nlrp3 promoter. (C) 293ET cells were transfected with 3 ng pRL-TK, 150 ng p65 plasmid, 300 ng Gﬁ1 expression plasmid or
pcDNA3.1 and 150 ng full-length Nlrp3 promoter or the mutants (nt 3033/+116) for 24 h. Luciferase activity was measured and normalized to that of Renilla luciferase. (D)
Nuclear extracts were prepared with Gﬁ1-transfected 293ET cells (left) and LPS-stimulated BMDMs (right). EMSA was performed with biotin-labeled Nlrp3 oligonucleotides
containing the Gﬁ1 binding site, GRE1. In competitive binding assays, 200-fold molar excess cold probe was added. The supershift bands indicate the complexes of Gﬁ1
antibody, Gﬁ1 protein and GRE1 element. (E) ChIP–PCR analysis of the promoter region of GRE1. BMDMs were stimulated with 100 ng/ml LPS for 1 h, protein–DNA complexes
were immunoprecipitated with anti-Gﬁ1 or control IgG antibody. The 1434/1113 region harboring GRE1 element was ampliﬁed by PCR assay. An irrelevant distal region
(nt 2269/2067) was ampliﬁed as the negative control. The relative intensities of the PCR bands were quantiﬁed and normalized to input control. ⁄P < 0.05; ⁄⁄⁄P < 0.001.
4516 L. Zhu et al. / FEBS Letters 588 (2014) 4513–4519p65 expression plasmids. As expected, the dual luciferase report
assay revealed signiﬁcant suppression of Nlrp3 transcription by
Gﬁ1 (Fig. 2A). Screening of the Nlrp3 promoter sequence further
disclosed two putative binding sites for Gﬁ1 located at positions
1210/1207 and 408/405 of the transcription start site. To
validate the functions of these two putative binding sites, mutant
reporter promoters (mutGRE1, mutGRE2 and mutGRE1/2) were
constructed and compared with the Gﬁ1 consensus binding site
[27], as depicted in Fig. 2B. Notably, mutation of GRE1 reversed
the inhibitory effect of Gﬁ1 while mutation of GRE2 had no inﬂu-
ence on Nlrp3 transcription (Fig. 2C).To further establish the effects of binding between GRE1 and
Gﬁ1, EMSA was performed with 293ET nuclear extracts and a
biotin-labeled probe containing GRE1. Compared with the Gﬁ1-
deﬁcient nuclear protein (lane 2 in the left panel and lane 3 in
the right panel), a shift band was observed in the Gﬁ1-expressing
nuclear protein (lane 3 in the left panel and lane 2 in the right
panel). The protein–DNA complex formation was remarkably
reduced with the unlabeled probe competition (Lane 4). The bind-
ing speciﬁcity was further veriﬁed by the supershift band with
anti-Gﬁ1 antibody (Lane 5). Consistent with this ﬁnding, a binding
shift was observed with nuclear extracts from BMDMs (Fig. 2D).
Fig. 3. Gﬁ1 suppresses Nlrp3 transcription by antagonizing the binding of NF-jB p65 and NRE1 elements. (A) Schematic of NRE1 and NRE2 positions in the Nlrp3 promoter.
(B) 293ET cells were transfected with 3 ng pRL-TK, 150 ng p65 expression plasmid or pcDNA3.1 and 150 ng functional Nlrp3 promoter mutants (nt 1434/1113) for 24 h.
Luciferase activity was measured and normalized to that of Renilla luciferase. (C) 293ET cells were transfected with p65 and Gﬁ1 plasmids, and nuclear extracts identiﬁed via
Western blot. EMSA was performed with biotin-labeled Nlrp3 oligonucleotides containing the NF-jB binding site, NRE1. In competitive binding assays, 200-fold molar excess
cold probe was added. ⁄⁄⁄P < 0.001.
Fig. 4. Functions of different domains in Gﬁ1. (A) Schematic diagram depicts the deletion of various regions in the Gﬁ1 protein. All of the mutants were recombinant with a
Flag-tag, and the expressions of them were detected byWestern blot. (B–D) 293ET cells were transfected with 3 ng pRL-TK, 150 ng p65 expression plasmid, 300 ng full-length
or mutant Gﬁ1 expression plasmids and 150 ng WT Nlrp3 promoter (nt 3033/+116) (B), 150 ng mutNRE1 promoter (nt 1434/1113) (C) or 150 ng mutGRE1 promoter (nt
3033/+116) (D) for 24 h. Luciferase activity was measured and normalized to that of Renilla luciferase. ⁄P < 0.05; ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001.
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The ChIP–PCR assay was additionally performed to determine
whether Gﬁ1 occupies the endogenous promoter site at GRE1.
The Nlrp3 promoter sequence containing GRE1 (proximal region)
was successfully ampliﬁed from precipitates with the anti-Gﬁ1
antibody, but not the IgG control sample. For the negative control,
the distal promoter region without GRE1 was not ampliﬁed from
any of the immunoprecipitates (Fig. 2E). Our results collectively
validate interactions between Gﬁ1 and GRE1 elements, bothin vivo and in vitro, and support direct transcriptional repression
of Nlrp3 by Gﬁ1.
3.4. Gﬁ1 inhibits Nlrp3 transcription indirectly by interfering with NF-
jB p65 activity
As speciﬁed earlier, mutation of both GRE1 and GRE2 did not
counteract inhibition by Gﬁ1 completely (Fig. 2C), signifying the
existence of other regulatory mechanisms. Accordingly, we further
Fig. 5. Both GRE1 and NRE1 elements are involved in negative regulation by Gﬁ1.
(A) A map of GRE1/NRE1 mutations in the Nlrp3 promoter region. (B) 293ET cells
were transfected with 3 ng pRL-TK, 150 ng p65 plasmid, 300 ng Gﬁ1 plasmid or
pcDNA3.1 and 150 ng Nlrp3 promoter mutants for 24 h. Luciferase activity was
measured and normalized to that of Renilla luciferase. ⁄P < 0.05.
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fering with NF-jB p65. Earlier, Qiao et al. identiﬁed two NF-jB
binding sites in the Nlrp3 promoter [20]. To avoid endogenous
inﬂuence, the dual luciferase reporter assay was performed with
293ET cells instead of macrophages. The Nlrp3 promoter was
transfected along with NF-jB binding site mutants (mutNRE1,
mutNRE2 and mutNRE1/2) into 293ET cells. Surprisingly, althoughFig. 6. Model for regulation of the NLRP3 inﬂammasome in macrophages. (A) LPS/ATP ind
be unregulated in the absence of Gﬁ1. (B) Gﬁ1 plays an essential role in controlling NLRP3
blocking the transcriptional activity of NF-jB p65.mutation of NRE1 almost completely suppressed activation of NF-
jB in the Nlrp3 promoter, mutation of NRE2 had no effect, and
mutation of both NRE1 and 2 induced a similar level of inhibition
as mutNRE1 (Fig. 3A and B). Our data indicate that NF-jB interacts
speciﬁcally with NRE1 for activation in this system.
To determine whether Gﬁ1 interferes with NF-jB binding to
NRE1, EMSA was performed with nuclear NF-jB p65 and Gﬁ1. As
shown in Fig. 3C, NF-jB p65 strongly interacted with the labeled
probe (lane 2). This binding was competed by Gﬁ1 (lane 3) and
excess cold probes (lane 4), suggesting that Gﬁ1 interferes with
NF-jB p65 binding to the Nlrp3 promoter.
3.5. SNAG domain and zinc-ﬁnger motif of Gﬁ1are indispensable for
regulation of Nlrp3
To clarify the speciﬁc domains that function in regulation of
Nlrp3 transcription, a series of Gﬁ1 mutants (depicted in Fig. 4A)
were adopted for the dual luciferase reporter assay. Signiﬁcantly,
all three domains were involved in the regulation of Nlrp3 tran-
scription (Fig. 4B). With the mutNRE1 promoter containing only
the GRE1 element, suppression by Gﬁ1 was abolished upon muta-
tion of either SNAG (Gﬁ1 DSNAG) or zinc ﬁnger (Gﬁ1 DZF)
domains, suggesting that intact SNAG domain and zinc ﬁnger
motifs are indispensable for GRE1-mediated regulation (Fig. 4C).
In contrast, with the mutGRE1 promoter containing only NRE1,
the inhibitory effect of Gﬁ1 was counteracted by deletion of the
intermediate region (Gﬁ1 DIM), indicating that this region is nec-
essary for NF-jB-dependent inhibition (Fig. 4D).
3.6. Gﬁ1 regulates the NLRP3 inﬂammasome via a ‘‘dual repression
model’’ mechanism
Next, we constructed an Nlrp3 promoter reporter with a NRE1/
GRE1 double mutant (Fig. 5A). As shown in Fig. 5B, upon mutation
of NRE1 and GRE1 separately, Gﬁ1 suppressed NF-jB-mediated
transcription of Nlrp3. Notably, maximal inhibition was attaineduce robust activation of the NLRP3 inﬂammasome. The inﬂammatory response may
expression and inﬂammasome activation by binding the GRE1 element directly and
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lectively imply that Gﬁ1 inhibits Nlrp3 transcription through dual
mechanisms: (1) direct binding of promoter DNA and (2) antago-
nizing NF-jB transcriptional activity. Upon mutation of the NRE1
element in the Nlrp3 promoter, the active signal of NF-jB was dis-
abled so that promoter activity was reduced to the fundamental
level. Our data suggest that Gﬁ1 is able to control Nlrp3 transcrip-
tion at both active and basal levels.
In summary, Gﬁ1 mediates regulation of NLRP3 expression
through a ‘‘dual repression mode’’ mechanism. Upon activation
by LPS, NF-jB promotes NLRP3 expression by binding the
cis-element, NRE1, and subsequently induces assembly of the
NLRP3 inﬂammasome to generate biologically active IL-1b
(Fig. 6A). Meanwhile, Gﬁ1 is induced to control LPS-induced
inﬂammation [30]. Gﬁ1 inhibits Nlrp3 transcription directly by
binding the GRE1 site with C-terminal zinc-ﬁnger motifs or blocks
NF-jB mediated Nlrp3 transcription through binding NF-jB p65
with the intermediate region. Both modes of action reduce IL-1b
release from macrophages in response to TLR stimulation
(Fig. 6B). It is worth mentioning that in response to LPS stimulation
alone, Gﬁ1-deﬁcient BMDMs exhibited a slight increase in IL-1b
production in culture medium than WT BMDMs (Fig. 1A). A possi-
ble explanation is that Gﬁ1 might inhibit the basal secretion of
IL-1b in an NLRP3 inﬂammasome-independent manner. Data from
the present study, in conjunction with previous reports, suggest
that Gﬁ1 restricts pro-IL-1b transcription and plays pivotal roles
in regulating IL-1b production at both the transcriptional and
post-translational levels. Our novel ﬁndings provide an ideal plat-
form for the development of effective anti-inﬂammatory therapies
to prevent IL-1b-induced tissue injury and mortality during sepsis.
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